The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

A new study published in the Journal of American Medical Association showed that subcutaneous nitroglycerin demonstrated ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

Okami Medical has closed a financing round, raising $45m, to expand its commercial presence and progress clinical programmes ...

FDA approves Regeneron's Eylea HD for retinal vein occlusion, adding extended dosing options and greater flexibility across ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO ...

The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

Okami Medical announced today that it appointed a new CEO alongside the closing of an oversubscribed $45 million financing.